France· FR:68373358
ULTRAVIST 300 (300 mg d'Iode/mL), solution injectable
A iopromide product containing iopromide, registered in France by BAYER HEALTHCARE, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Iopromide is registered in 13 of 19 countries.
Countries holding a registration under ATC V08AB05 (iopromide), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Iopromide · ATC V08AB05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IOPROMIDE
- Manufacturer
- BAYER HEALTHCARE
- Country
- France (FR)
- ATC code
- V08AB05
- ATC class
- Iopromide
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 13
1 priced- cip1334009330904011 flacon(s) en verre de 100 ml
- cip1334009376037821 flacon(s) en verre de 150 ml
- cip1334009277971491 flacon(s) en verre de 100 mL avec nécessaire d’administration pour injecteur MEDRAD Stellant : seringue vide de 200 mL + raccord spiralé + microperfuseur de remplissage et cathéter de sécurité à ailettes I.V. 20G
- cip1334009302055941 flacon(s) en verre de 100 mL avec nécessaire d'administration pour injecteur MEDRAD Centargo : raccord patient et cathéter de sécurité à ailettes I.V. 20G
- cip1334009302056001 flacon(s) en verre de 150 mL avec nécessaire d'administration pour injecteur MEDRAD Centargo : raccord patient et cathéter de sécurité à ailettes I.V. 20G
- cip1334009302838998 flacon(s) en verre de 500 ml
- cip1334009330903401 flacon(s) en verre de 50 ml
- cip13340095592123310 flacon(s) en verre de 200 ml
- cip13340095595570210 flacon(s) en verre de 20 ml
- cip13340095595587010 flacon(s) en verre de 50 ml
- cip13340095595593110 flacon(s) en verre de 100 ml
- cip13340095638517110 flacon(s) en verre de 150 ml
- cip1334009330902891 flacon(s) en verre de 20 mlEUR 7.04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
232 interactions on record for iopromide.
Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Iopromide · interactions on record
232 records
- 94 severe
- 55 moderate
- 83 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Iopromide in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaULTRAVISTBayer AG, Leverkusen
- BelgiumUltravist 240 240 mg/mlBayer
- United KingdomUltravist 150 solution for injection 50ml vialsBayer Plc
- Japanイオプロミドバイエル薬品
- GermanyUltravist 300Eurocontrast Gmbh
- United StatesUltravistBayer HealthCare Pharmaceuticals Inc.
- SwedenUltravist 150 mg I/ml Injektions-/infusionsvätska, lösningBayer AB
- FinlandUltravistBayer Oy
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Ultravist
- Belgium · Ultravist
- Bulgaria · Ултравист
- Cyprus · Ultravist 300, Ultravist 370
- Czechia · Ultravist
- Germany · Ultravist 300, Ultravist-240
- Denmark · Ultravist
- Estonia · Ultravist
- Spain · Ultravist
- Greece · Ultravist
- Croatia · Ultravist
- Hungary · Ultravist
- Italy · Ultravist
- Lithuania · Ultravist
- Luxembourg · Ultravist
- Latvia · Ultravist
- Malta · Ultravist 370
- Netherlands · Ultravist
- Norway · Ultravist
- Poland · Ultravist 300, Ultravist 370
- Portugal · Ultravist 240, Ultravist 300
- Romania · Ultravist
- Sweden · Ultravist
- Slovenia · Ultravist
- Slovakia · Ultravist
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4f5feb9d-a980-45fb-a4dc-46fe9875509f GET /v1/drugs/4f5feb9d-a980-45fb-a4dc-46fe9875509f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68373358",
"date_amm": "1988-05-06",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "IOPROMIDE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intra-utérine;intraarticulaire;intraartérielle;intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about iopromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.